Loading news...
BASEL, Switzerland and LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 6, 2026, to report its financial results for the second quarter ended December 31, 2026, and provide a business update.
Campbell and CO Investment Adviser LLC trimmed its holdings in Roivant Sciences Ltd. (NASDAQ: ROIV) by 65.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 35,753 shares of the company's stock after selling 68,705 shares during the period. Campbell and CO
Roivant Sciences (NASDAQ: ROIV - Get Free Report) and NovAccess Global (OTCMKTS:XSNX - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership. Analyst Recommendations This is a breakdown of current
Roivant Sciences Ltd. (ROIV) Presents at 44th Annual J.P.
Roivant Sciences Ltd. (ROIV) Q2 2025 Earnings Call Transcript
Stock News Street sets 2026 expectations: Wall Street sees the S&P 500 posting modest-to-mid-teens gains in 2026 after a 16.39% rise in 2025, with AI leaders li
Roivant Sciences Ltd. (NASDAQ: ROIV - Get Free Report) CEO Eric Venker sold 75,000 shares of the stock in a transaction on Wednesday, December 24th. The stock was sold at an average price of $22.53, for a total transaction of $1,689,750.00. Following the sale, the chief executive officer directly owned 1,654,597 shares of the company's stock,
The Goldman Sachs Mid Cap Growth Fund underperformed its benchmark, the Russell Midcap Growth Index (net), during the quarter. United Rentals, Inc. released a positive quarterly earnings report, surpassing earnings expectations and raising future guidance, which the street responded favorably toward. Roivant Sciences Ltd.'s stock price soared during the period following the release of positive data for a drug it is developing that aims to treat inflammatory autoimmune diseases.
Roivant Sciences Ltd. (NASDAQ: ROIV - Get Free Report) CEO Eric Venker sold 200,000 shares of the stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $20.85, for a total value of $4,170,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,497,908 shares of
Roivant Sciences Ltd. (ROIV) Analyst/Investor Day Transcript
Roivant (NASDAQ: ROIV) outlined accelerated timelines and expanded commercial ambitions for several late-stage programs.
BASEL, Switzerland and LONDON and NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today is hosting an Investor Day in New York City. Roivant leadership will highlight key pipeline updates and provide an update on the Company's strategy for long-term value creation.
Roivant Sciences Ltd. (NASDAQ: ROIV - Get Free Report) shares hit a new 52-week high on Friday. The stock traded as high as $21.40 and last traded at $21.1550, with a volume of 1946 shares. The stock had previously closed at $21.18. Analyst Ratings Changes Several equities analysts have recently weighed in on ROIV shares.
Representative Lisa C. McClain (R-Michigan) recently sold shares of Roivant Sciences Ltd. (NASDAQ: ROIV). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in Roivant Sciences stock on October 31st. The trade occurred in the Representative's "CHARLES SCHWAB 401K > SCHWAB 893" account. Representative Lisa C. McClain
Roivant Sciences Ltd. ( ROIV ) Jefferies London Healthcare Conference 2025 November 18, 2025 12:00 PM EST Company Participants Matthew Gline - CEO & Director Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Presentation Yuchen Ding Jefferies LLC, Research Division Good afternoon.
ROIV's holding-company model with its Vants continues creating shareholder value. They then recycle M&A and partnership proceeds into late-stage assets. ROIV focuses on autoimmune and rare-disease drug programs. Recent promising Phase 3 data for DM with Brepocitinib have helped the stock appreciate. Brepocitinib could tap into a sizeable TAM over time, and its NDA filing for DM is expected by 1H2026. Plus, it can target NIU and CS.
Roivant Sciences Ltd. ( ROIV ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 11, 2025 8:00 AM EST Company Participants Richard Pulik - Chief Financial Officer Conference Call Participants Yatin Suneja - Guggenheim Securities, LLC, Research Division Presentation Yatin Suneja Guggenheim Securities, LLC, Research Division All right.
Roivant Sciences Ltd. ( ROIV ) Q2 2026 Earnings Call November 10, 2025 8:00 AM EST Company Participants Stephanie Lee Griffin - Chief Operating Officer of Roivant Platforms Matthew Gline - CEO & Director Conference Call Participants David Risinger - Leerink Partners LLC, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Samantha Semenkow - Citigroup Inc., Research Division Yaron Werber - TD Cowen, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Corinne Jenkins - Goldman Sachs Group, Inc., Research Division Yuchen Ding - Jefferies LLC, Research Division Dominic Risso-Gill Douglas Tsao - H.C.
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.27.
BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2025, and provided a business update. Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all nine key secondary endpoints in Phase 3 VALOR study in dermatomyositis (DM), with NDA filing planned for the first half of calendar year 2026 Brepocitinib program continues to advance with rapid enrollment in Phase 3 study in non-infectious uveitis (NIU) and proof-of-concept trial in cutaneous sarcoidosis (CS), with readouts expected in the first half of calendar year 2027 and second half of calendar year 2026, respectively Immunovant study in uncontrolled Graves' disease (GD) patients treated for 24 weeks showed first-ever potentially disease-modifying outcome with six-month off-treatment data.